两性小分子抗微生物:从阴离子抗微生物 (CAMP) 到与机制相关的,结构多样化的抗微生物
Jiani Yuan1, Jiaxing Wang2, Xiaoxue Li3
1Department of Neurology, Joint Research Institution of Altitude Health and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
新型小分子抗微生物药物为打击抗生素耐药性的上升提供了有希望的解决方案. 这些化合物具有成本效益,稳定性和毒性较低,解决了当前治疗方法的关键局限性.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 细菌感染导致显著的发病率和死亡率.
- 由于滥用导致抗生素耐药性的增加,需要新的治疗策略.
- 抗微生物具有前景,但面临诸如高成本,不稳定性和细胞毒性等挑战.
研究的目的:
- 审查最近在小分子宿主防御的两性抗微生物药物方面的进展.
- 探索这些新型剂的设计,特性和应用.
- 突出新兴的查方法,用于新的抗微生物药物开发.
主要方法:
- 关于小分子两性抗菌素的最新研究的文献综述.
- 分析设计概念,结构-活动关系和类似药物的特性.
- 评估抗微生物活性,体内稳定性和细胞毒性.
主要成果:
- 小分子两性抗微生物药物显示出克服细菌耐药性的潜力.
- 这些药物在成本,稳定性和安全性方面比传统的抗微生物具有优势.
- 新兴的查方法正在改善新型抗菌候选药物的识别.
结论:
- 小分子两性抗微生物药物是解决迫切需要新抗菌药物的可行替代品.
- 在这个领域进行进一步的研究和开发可以减轻当前抗菌剂的缺陷.
- 本综述为未来抗菌药物治疗的药物发现和开发提供了洞察力.
相关概念视频
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Chemical Agents for Microbial Control
Biological Methods for Microbial Control
Gene Regulation in Microbial Communities: Quorum Sensing
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...


